Another potential molecule-based therapy for CF is thymosin α1 (Tα1), a naturally occurring polypeptide with an excellent safety profile that has been shown to rectify multiple CF tissue defects in CF KO mice and tissues from patients with F508del mutations [150]. The gene discussed is TAAR1; the disease is cystic fibrosis.